Amarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Amarin (NASDAQ:AMRN) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02, Yahoo Finance reports. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. During the same period in the prior year, the firm posted ($0.04) earnings per share.

Amarin Stock Up 6.6 %

Shares of NASDAQ AMRN traded up $0.06 on Thursday, hitting $0.90. The company had a trading volume of 790,349 shares, compared to its average volume of 1,932,692. Amarin has a 12-month low of $0.65 and a 12-month high of $1.49. The business has a 50 day moving average of $0.95 and a two-hundred day moving average of $0.94. The firm has a market capitalization of $367.55 million, a P/E ratio of -6.05 and a beta of 1.95.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $1.08.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.